Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2Gastrointestinal 2Sarcoma 1

Conditions

Colorectal Neoplasms 81Colonic Neoplasms 18Neoplasm Metastasis 17Rectal Neoplasms 14Neoplasms 13Stomach Neoplasms 7Carcinoma, Non-Small-Cell Lung 5Pancreatic Neoplasms 4Ovarian Neoplasms 4Lung Neoplasms 4Gastrointestinal Neoplasms 4Carcinoma, Renal Cell 3Carcinoma, Neuroendocrine 3Uterine Cervical Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Melanoma 2Lymphoma, Non-Hodgkin 2Leukemia, Myeloid, Acute 2Breast Neoplasms 2Brain Neoplasms 2Adenocarcinoma 2Urinary Bladder Neoplasms 1Unresectable Metastatic Colorectal Cancer 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Solid Tumors 1Small Cell Lung Carcinoma 1Sarcoma 1Ras-mutated Metastatic Colorectal Cancer 1Prostatic Neoplasms 1

Interventions

Cytarabine 561Azacitidine 384venetoclax 310Cyclophosphamide 289fludarabine 246fludarabine phosphate 229Decitabine 186Busulfan 176Daunorubicin 155Idarubicin 150Peripheral Blood Stem Cell Transplantation 138Mycophenolic Acid 134Filgrastim 134Whole-Body Irradiation 133Tacrolimus 125Granulocyte Colony-Stimulating Factor 124Etoposide 117Mitoxantrone 103Methotrexate 103Melphalan 103Cyclosporine 101Antilymphocyte Serum 85Gemtuzumab 84Clofarabine 84Specimen Handling 72Injections 69Stem Cell Transplantation 64Biopsy 57CPX-351 56Thiotepa 54

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Leukemia, Myeloid, Acute × IFL protocol × Clear all
NCT04553692 2025-03-28

Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers

IGM Biosciences, Inc.

Phase 1 Terminated
272 enrolled
GastrointestinalLymphoidOther hematologic neoplasmSarcoma

Chondrosarcoma, Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Sarcoma, Colorectal Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute

NCT03082209 2022-12-09

A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously-Treated Solid Tumors and Hematologic Malignancies

AbbVie

Phase 1 Completed
153 enrolled
GastrointestinalLymphoidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Neoplasms, Colorectal Neoplasms, Leukemia, Myeloid, Acute, Lymphoma, Large B-Cell, Diffuse, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡